A comparison study of the cytotoxicity of salinomycin and salinomycin sodium toward human breast cancer stem cells as well as breast cancer cells

doi:10.5246/jcps.2011.04.046

Abstract

Abstract: Salinomycin (SAL), a polyether antibiotic isolated from Streptomyces albus, is widely used as an anticoccidial drug in poultry and other livestock and is furthermore fed to ruminescent animals to improve nutrient absorption and feed efficiency. It has recently been shown to act as a specific inhibitor of cancer stem cells. At present, the price of salinomycin sodium (SAL-Na) is 10 fold lower than that of salinomycin, however, there is no report about the comparison of the inhibitory effects of SAL and SAL-Na on cancer stem cells as well as cancer cells. In the present study, side population cells (SP cells) and non-SP cells (NSP cells) sorted from human breast cancer cell line MCF-7 were chosen as the models of cancer stem cells and cancer cells, respectively. SRB assay was performed to compare the cytotoxicity of SAL and SAL-Na. First of all, SP cells were sorted from MCF-7 cells via FACSDiva flow cytometry. Secondly, the sorted SP cells were identified with the surface makers (CD44⁺/CD24^-) of breast cancer stem cells. Finally, the inhibitory effects of SAL and SAL-Na were evaluated on the sorted SP cells and NSP cells. Results showed that, as compared to breast cancer cells, the inhibitory effect of free SAL or free SAL-Na was more potent in breast cancer stem cells. Furthermore, the inhibitory effects of free SAL and free SAL-Na had no significant difference for the SP cells as well as the NSP cells when they were in the same concentration. Thus, it suggested that salinomycin sodium should be considered as a potential candidate to take the place of salinomycin in cancer stem cells research, due to their similar inhibitory effects on cancer stem cells.

Key words: Salinomycin, Salinomycin sodium, Cancer stem cells, Human breast cancer cell line MCF-7

CLC Number:

Supporting:

Yang Zhang, Xue-Qing Wang, Jian-Cheng Wang, Xuan Zhang, Qiang Zhang^*. A comparison study of the cytotoxicity of salinomycin and salinomycin sodium toward human breast cancer stem cells as well as breast cancer cells[J]. , DOI: 10.5246/jcps.2011.04.046.

References

[1] Miyazaki, Y.; Shibuya, M.; Sugawara, H.; Kawaguchi, O.; Hirsoe, C. J. Antibiot. 1974, 27, 814-821.
[2] Mahmoudi, N.; De Julian-Ortiz, J.V.; Ciceron, L.; Galvez, J.; Mazier, D.; Danis, M.; Derouin, F.; Garcia-Domenech, R. J. Antimicrob. Chemother. 2006, 57, 489-497.
[3] Danforth, H.D.; Ruff, M.D.; Reid, W.M.; Miller, R.L. Science. 1977, 56, 926-932.
[4] Callaway, T.R.; Edrington, T.S.; Rychlik, J.L.; Genovese, K.J.; Poole, T.L.; Jung, Y.S.; Bischoff, K.M.; Andersson, R.C.; Nisbet, D.J. Curr. Issues Intest. Microbiol. 2003, 4, 43-51.
[5] Gupta, P.B.; Onder, T.T.; Jiang, G.; Tao, K.; Kuperwasser, C.; Weinberg, R.A.; Lander, E.S. Cell. 2009, 138, 645-659.
[6] Fuchs, D.; Daniel, V.; Sadeghi, M.; Opelz, G.; Naujokat, C. Biochem. Biophys. Res. Commun. 2010, 394, 1098-1104.
[7] Pressman, B.C. Annu. Rev. Biochem. 1976, 45, 501.
[8] Hadnagy, A.; Gaboury, L.; Beaulieu, R.; Balicki, D. Exp. Cell Res. 2006, 312, 3701-3710.
[9] Wu, C.; Alman, B.A. Cancer Lett. 2008, 268, 1-9.
[10] Goodell, M.A.; Brose, K.; Paradis, G.; Conner, A.S.; Mulligan, R.C. J. Exp. Med. 1996, 183, 1797-1806.
[11] Donnenberg, V.S.; Landreneau, R.J.; Donnenberg, A.D. J. Control. Release. 2007, 122, 385-391.
[12] Kondo, T.; Setoguchi, T.; Taga, T. Proc. Natl. Acad. Sci. USA. 2004, 101, 781-786.

[13] Hirschmann-Jax, C.; Foster, A.E.; Wulf, G.G.; Nuchtern, J.G.; Jax, T.W.; Gobel, U.; Goodell, M.A.; Brenner, M.K. Proc. Natl. Acad. Sci. USA. 2004, 101, 14228-14233.
[14] Mitsutake, N.; Iwao, A.; Nagai, K.; Namba, H.; Ohtsuru, A.; Saenko, V.; Yamashita, S. Endocrinology. 2007, 148, 1797-1803.
[15] Chiba, T.; Kita, K.; Zheng, Y.W.; Yokosuka, O.; Saisho, H.; Iwama, A.; Nakauchi, H.; Taniguchi, H. Hepatology. 2006, 44, 240-251.
[16] Szotek, P.P.; Pieretti-Vanmarcke, R.; Masiakos, P.T.; Dinulescu, D.M.; Connolly, D.; Foster, R.; Dombkowski, D.; Preffer, F.; Maclaughlin, D.T.; Donahoe, P.K. Proc. Natl. Acad. Sci. USA. 2006, 103, 11154-11159.
[17] Seigel, G.M.; Campbell, L.M.; Narayan, M.; Gonzalez-Fernandez, F. Mol. Vis. 2005, 11, 729-737.
[18] Wulf, G.G.; Wang, R.Y.; Kuehnle, I.; Weidner, D.; Marini, F.; Brenner, M.K.; Andreeff, M.; Goodell, M.A. Blood. 2001, 98, 1166-1173.
[19] Al Hajj, M.; Wicha, M.S.; Benito-Hernandez, A.; Morrison, S.J.; Clarke, M.F. Proc. Natl. Acad. Sci. USA. 2003, 100, 3983-3988.
[20] Collins, A.T.; Berry, P.A.; Hyde, C.; Stower, M.J.; Maitland, N.J. Cancer Res. 2005, 65, 10946-10951.
[21] Raaijmakers, M.H.; Grouw, E.P.; Heuver, L.H.; Van der Reijden, B.A.; Jansen, J.H.; Scheper, R.J.; Scheffer, G.L.; De Witte, T.J.; Raymakers, R.A. Clin. Cancer Res. 2005, 11, 2436-2444.
[22] Zhou, J.; Wulfkuhle, J.; Zhang, H.; Gu, P.; Yang, Y.; Deng, J.; Margolick, J.B.; Liotta, L.A.; Petricoin III, E.; Zhang, Y. Proc. Natl. Acad. Sci. USA. 2007, 104, 16158-16163.
[23] Vichai, V.; Kirtikara, K. Nat. Protoc. 2006, 1, 1112-1116.
[24] Kuperwasser, C.; Chavarria, T.; Wu, M.; Magrane, G.; Gray, J.W.; Carey, L.; Richardson, A.; Weinberg, R.A. Proc. Natl. Acad. Sci. USA. 2004, 101, 4966-4971.
[25] Grichnik, J.M.; Burch, J.A.; Schulteis, R.D.; Shan, S.; Liu, J.; Darrow, T.L.; Vervaert, C.E.; Seigler, H.F. J. Invest. Dermatol. 2006, 126, 142-153.
[26] Lopez de Cicco, R.; Bassi, D.E.; Zucker, S.; Seidah, N.G.; Klein-Szanto, A. J. Cancer Res. 2005, 65, 4162-4171.
[27] Camargo, F.D.; Chambers, S.M.; Drew, E.; McNagny, K.M.; Goodell, M.A. Blood. 2006, 107, 501-507.
[28] Liu, Y.; Lu, W.L.; Guo, J.; Du, J.; Li, T.; Wu, J.W.; Wang, G.L.; Wang, J.C.; Zhang, X.; Zhang, Q. J. Control. Release. 2008, 129, 18-25.